DNA Chip Based Prognosis of Lung Cancer

Medical Prognosis Institute A/S144 enrolled

Overview

The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).

Study Type

OBSERVATIONAL

Enrollment

144

Conditions

Carcinoma, Non-Small-Cell Lung

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. A histological diagnosis of primary NSCLC stage Ia 2. Surgical removal of the tumor 3. Age between 18 and 75 years 4. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery. 2. Adjuvant treatment with chemotherapy. 3. Prior history of cancer in the past 5 years or breast cancer at any time. 4. Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.

Locations (5)

University of Alabama

Birmingham, Alabama, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

Aarhus University Hospital

Aarhus, Denmark

University of Copenhagen

Copenhagen, Denmark

Outcomes

Primary Outcomes

Disease-related survival

Time frame: 5 years

Secondary Outcomes

Time to progression

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.